

Keith Chadwick

Senior Patent Agent
Gemini Law LLP



kchadwick@geminilaw.com

LANGUAGE

- English

ADMISSIONS

- U.S. Patent & Trademark

Dr. Keith Chadwick is a senior patent agent at Gemini. Keith has ~8 years experience in intellectual property matters at leading U.S. law firms. Prior to joining Gemini, he worked at Goodwin and Wilson Sonsini. He holds a Bachelor's of Science degree with honors in chemistry and a Ph.D. in chemical engineering from the University of Manchester, United Kingdom.

Keith's practice includes advising companies and investors on intellectual property matters, specializing in patent prosecution within the chemistry, life sciences, and materials science sectors. Specifically, this involves collaborating with the executive and R&D teams of companies to design and implement business-focused IP strategies to build and manage robust patent portfolios. Keith has enjoyed working with companies at various stages of their lifecycle, from early-stage to post-approval. He has a wealth of experience in drafting and prosecuting patents in a wide range of technical fields, including small molecule drug design, formulation, solid form chemistry, methods of treatment, drug delivery, liposomal/nanoparticle technologies, bio-materials, and polymeric materials.

Keith brings extensive experience in competitive landscape evaluation, freedom-to-operate analysis, and IP due diligence for complex transactions, including financings, IPOs, and mergers and acquisitions.

Prior to working in intellectual property law, Keith was Assistant Professor at Purdue University in the Department of Industrial and Physical Pharmacy. He led a research group focused on pharmaceutical development and manufacturing. He is an expert in formulation and solid form chemistry and has extensive expertise in drug delivery, polymer chemistry, chemical engineering, pharmaceutical manufacturing, nanotechnology, and materials science.

Keith has also done postdoctoral research at the MIT-Novartis Center for Continuous Manufacturing in Cambridge, Mass. and the Department of Chemical Engineering, UMIST in Manchester, UK.

Keith has published extensively in peer-reviewed journals, including J. Pharm. Sci., Organic Process Research & Development, Carbohydrate Polymers, and CrystEngComm.

SELECT PUBLICATIONS (3 of 21)

- P. Kavuru, S. J. Grebinoski, M. A. Patel, L. Wojtas, **K. Chadwick**; *Polymorphism of vanillin revisited: the discovery and selective crystallization of a rare crystal structure*; CrystEngComm; 18; 2016; 1118-1122.
- M. Patel, M. AbouGhaly, J. Schryer-Praga, **K. Chadwick**; *The Effect of Ionotropic Gelation Residence Time on the Pharmaceutical Properties of Drug Containing Alginate Particles*; Carbohydrate Polymers; 2017; 155; 362-371.
- J. Ling, **K. Chadwick**; *Heterogeneous Crystallization Inside Microporous Particles as a Process Intensification Technology for the Manufacture of Drug Formulations*; Organic Process Research and Development (2017); DOI: 10.1021/acs.oprd.6b00380

CREDENTIALS

Education

- PhD in Chemical Engineering, University of Manchester Institute of Science & Technology (UMIST), Department of Chemical Engineering
- BSc (Hons) in Chemistry, UMIST, Department of Chemistry

Admissions

- United States Patent and Trademark Office

Membership

- Intellectual Property Law Association of Chicago

Awards

- NSF grant: US-Ireland Partnership in Continuous Manufacturing, investigator (2016)
- Research Starter Grant from PhRMA: Controlling Crystallization in Microporous Polymeric Excipients for the Advanced Manufacture of Drug Formulations, principal investigator (2015)
- Purdue Research Foundation Faculty Summer Grant, principal investigator (2013 and 2015)
- Purdue Research Foundation Faculty International Travel Award, principal investigator (2014)
- Purdue Graduate Student Summer Fellowship, mentor (2013 and 2015)
- Purdue Research Foundation Graduate Fellowship, mentor (2015)
- Lilly Endowment Graduate Fellowship, mentor (2014)

Patents

- K. Chadwick, B. L. Trout, A. S. Myerson; *Methods and systems relating to the selection of substrates comprising crystalline templates for the controlled crystallization of molecular species*; US 9,822,467B2. Licensed by Continuous Pharmaceuticals, Woburn, Massachusetts.